Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

2017

Dermatologic adverse events associated with Juvenile Idiopathic Arthritis treatment

2020

Introduction: Steroids and disease-modifying anti-rheumatic drugs (DMARDs) are widely used in the treatment of juvenile idiopathic arthritis (JIA). Dermatologic adverse events including psoriasis have been reported in treatment of various inflammatory diseases (1-3). However, data regarding the occurrence of dermatologic adverse events in JIA patients are scarce (4-6). Objectives: To determine the prevalence of dermatologic adverse events in JIA patients treated with systemic steroids and DMARDs. To investigate an association between drugs and dermatologic adverse events and the association between anti-TNF treatment and psoriasiform lesions.

Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

2017

Adherence to colchicine treatment and colchicine resistance in a multicentric FMF national cohort

2020

Introduction: Colchicine is the standard treatment for Familiar Mediterranean Fever (FMF), however about 5% of patients (pts) experience colchicine resistance. There is no standard definition of colchicine resistance. Recently a panel of experts elaborated a new definition based on a Delphi consensus approach. Objectives: We aim to describe main features of the disease and clinical outcome of a cohort of FMF pts with particular interest on the colchicine resistance and tolerability according to the definitions proposed by the recent consensus.